cells in the jeopardized zone. Concerning the data on treated patients the treatment was started 13 hours after the onset of chest pain,1' 2 and it is hard to understand that the effect of treatment at this stage can be so extensive. According to the computed curves most of the irreversible damage is already done, and the cells that are candidates for salvage at this point seem to be only a small portion of the total. Yet the authors describe a reduction of infarct size from 53 CPK gram-equivalents to 27 in the reported case of trimetaphane treatment in a hypertensive patient.
The work referred to has gained much attention and in principle the hypothesis is extremely interesting. Based on the published data, however, the reader is left with serious doubts as to whether there is not an effect on the CPK activity of the already released amount of enzyme that overshadows the effect that the authors are really looking for.
We would appreciate an explanation from the authors on these two points.
E. LORENTSEN, M.D. D. SCOTT 1976 The authors reply:
Dr. Lorentsen and colleagues raise two related concerns. The first, namely that the prompt drop in CK, is not explicable by salvage of jeopardized tissue, fails to reflect available information regarding the elimination of enzyme from blood. It is now clear that the rate of disappearance of CK after infarction is substantially slower than disappearance after intravenous injection of enzyme, at least in part because of continued release of CK into the circulation after plasma CK has peaked. When zymosan is administered after myocardial infarction, inhibiting CK disappearance, observed plasma activity actually increases substantially even when zymosan is given after plasma CK activity has begun to decline. The decline of activity from blood is markedly decreased by even modest late release from the heart and does not produce striking deviations from linear fits of semi-log plots of CK timeactivity curves.'-3 Since the observed elimination rate of CK from blood after infarction reflects not only the true CK disappearance rate but also continuing release from the heart with concomitant resupply of the vascular space, inhibition of enzyme release by an intervention would indeed cause the elimination rate to exceed that prevailing alter a typical myocardial infarction. 4 The second concern is based on the unsupported assumption that interventions initiated relatively late will be totally ineffective. In hypertensive patients, continuing damage to the heart may occur for substantially longer intervals than in patients with infarction without hypertension. The time dependent evolution of necrosis cannot be deduced from computed curves, since such curves are based only on empirical associations between early and late plasma CK values in groups of patients. The prejudice that damage occurs early is one with which we concur, but we do not concur with the concept that damage occurs early exclusively. In addition to obser-vations indicating that late CK release is typical, frequent extension or repeat infarction has been recognized.5 Since it is probable that at least some of these events occur relatively early during the inscription of plasma CK time-activity curves, they would contribute to the characteristic shape of such curves, which have not been explicable in terms of a single pulse of enzyme release during a very brief interval.1 6 Improved interpretation of plasma CK time-activity curves after myocardial infarction with or without interventions requires elucidation of physiological processes governing myocardial CK release from the heart, transport into the circulation (in part via lymph), and removal or inactivation.7 Considerable progress has been made in clarifying some of these processes and defining their contributions to plasma CK time-activity curves after experimental or spontaneous myocardial infarction. The assumptions underlying the surprise expressed by Lorentsen and co-workers are not supported by available data suggesting that continued CK release does in fact occur characteristically and that it contributes to a disparity between the true CK disappearance rate and the observed rate of elimination of CK from blood. Accordingly, it is not surprising that reduction or interruption of enzyme release by an intervention would produce a rapid decline in plasma CK activity compared to the generally prevailing elimination rate which includes a component reflecting continuing release become the most certain noninvasive method of detecting ventricular aneurysms. They are, however, in error when they state that "data suggesting that M-mode echocardiography might be useful in detecting ventricular aneurysms have appeared only in the form of isolated case reports. " We described nine patients, eight of whom had aneurysms in-130 CIRCULATION LETTERS TO THE EDITOR volving the anterior wall of the left ventricle and one who had an inferior aneurysmal bulge confirmed by ventriculography.' As Weyman et al. correctly have noted, the M-mode scan frequently failed to show the tapering that normally occurs as the beam traverses the peri-apical region. However, in addition to that finding (which we could not consistently obtain) we noted that in the eight patients with anterior aneurysm there was a convex systolic anterior motion of the mitral valve which resembled, yet was distinctly different from, the so called SAM usually seen in IHSS. This finding was absent in the patient who had the inferior wall aneurysm. Although SAM is nonspecific, it does provide a definite clue, when correctly correlated with the clinical findings, toward the diagnosis of ventricular aneurysm. For those echocardiographers who have yet to acquire cross-sectional capability this information should prove useful. JONATHAN G. GREENWALD, M.D., F.A.C.P.
Section of Cardiology
Norwalk Hospital Norwalk, Connecticut 
Effect of Electrode Area on V ECG
To the Editor: It was with some concern that I read the article by Hughes et al. "Failure of Demand Pacing with Small Surface Area Electrodes" (Circulation 54: 128, 1976). The authors correctly point out that decreasing surface area of electrodes is associated with decreasing energy requirements for cardiac stimulation but add, incorrectly, that "small" area electrodes are associated with poor detection of the ventricular electrogram and that failure of QRS sensing by a pulse generator will occur. They make the statement "Recent reports indicate a failure rate (sic. sensing) as high as 15%." Two publications were cited. One, from 1968 (authors' ref. 9) addressed itself solely to the problem of poor development of the intracardiac potential in the specific instance of and as a complication of acute myocardial infarction and pointed out that with clinical improvement the amplitude of the intracardiac potential increased and sensing was restored, without electrode change. No information aside from the unipolar nature of the electrode was given and no inference concerning the electrode size is possible. It was in this publication that the failure of sensing of 15% (6 of 40 patients with acute myocardial infarct) was given.' The second reference, from 1970, (authors' ref. I 1) concerns itself with the operation of a pacemaker clinic, in which no electrode is listed by model number or size and in which, on two occasions the reversion of a pacemaker to a fixed rate, insensitive mode of operation was used as an indication of " . . . the first sign of battery failure,"2 and not of a problem with the electrode or its size. Again no evidence is given in that paper to indicate the incidence of sensing failure or that such failures were other than indicators of a depleted and thus failing pulse generator. Neither reference supports the contention in the Hughes paper and thus neither reference was correctly used.
The evaluation of sensing failure in a specific clinical situation can involve a complex analysis, only one factor of which may be the pacer and/or electrode. The title suggests a clinical experience or one with immediate clinical relevance but except for the literature review, no illustrative clinical situation was addressed. The differences between the clinical and animal laboratory circumstances were not adequately addressed.
The conclusions of the study are faulty because of an error signalled in the first sentence of the "Discussion." "This study shows that the ability to detect R-wave potentials in low im-pedance systems . " (The authors used 1000 ohm load). They correctly state " with small surface area electrodes, pacemaker circuit impedance becomes a major determinant of the amplitude of the R-wave signal recorded." Then the study proceeds with a pulse generator input impedance-appropriate to low impedance, large surface area electrodes discontinued by the manufacturer (Medtronic, Inc., Brennan, T. -Personal Communication -August 30th, 1976) and disregards the input impedance appropriate for the presently available small electrodes. The pacemaker industry has not used sensing input impedances less than 4000 ohms for the past five years or more. The authors state that " . . the current trend is toward high pacemaker circuit impedance (20,000 ohms or greater)." That is now and has been the design practice for the past five years. They quote one manufacturer who suggested that the Cordis ball tip electrode not be used with his unit but not the change in recommendation. Once the design characteristic of low input imedance was recognized, it was altered by an increase in input impedance and elimination of that recommendation. (Cardiac Pacemakers Inc. -Maki, K. -Personal Communication -August 26th, 1976).
In effect, the problem of poor sensing of the QRS complex was one of mismatch between the high impedance of a smaller electrode with the lower pacer sensing impedance, suitable for a larger, lower impedance electrode (from an earlier era) but not suitable for the smaller. That problem was addressed and has been corrected, but not by the flat statement that the signal from the small electrode is poor. The signal is not poor, but its sensing is affected by proper (or improper) match of the input amplifier impedance of the pacer and the impedance of the electrode. 1) Small surface area electrodes very definitely decrease the size of the R-wave detected by a pacemaker sensing circuitregardless of the sensing circuit impedance.' Even at infinite impedance, small surface area electrodes reduce the cardiac electrogram a minimum of 25%. Dr. Furman presents no data to support his contrary opinion.
2) The references quoted in the introduction and objected to by Dr. Furman verify that sensing problems were not infrequent even with large surface area electrodes. No attempt was made by us to link all past sensing failures to small surface area electrodes.
3) We were, however, led to perform our study by the increased incidence of sensing failures in our own clinical practice, of from approximately 1% prior to the introduction of the small surface area electrode to in the range of from 3 to 5% following their introduction (see page 131). Others have noted a similar association. 4) Dr. Furman's comments regarding what he calls matching of circuit and electrode impedances are oversimplified. High impedance (low load) circuits result in less attenuation of the R-wave signal regardless of electrode size. But the high impedance sensing circuits become critical and essential with small surface area electrodes and as the discussion section of our paper points out, this high impedance cannot be assured in a potentially wet and shorted system. Recent problems with the Xytron2 offer ample evidence of the development of low impedance pathways within implanted pacemakers. Dr. Furman is incorrectly assuming that the circuit impedances measured on the bench prior to pacemaker implantation will be the same as the impedances present following implantation into the hostile biological environment. Even hermetic sealing does not totally eliminate this problem as connector leaks may, under certain circumstances, severely load the R-wave transmission-sensing circuit system. As far as the earlier and now cor-
